Oculis (NASDAQ:OCS) Shares Up 7.2% – Time to Buy?

Oculis Holding AG (NASDAQ:OCS)’s stock price shot up 7.2% during trading on Wednesday . The company traded as high as $12.87 and last traded at $13.1750. 948,993 shares changed hands during mid-day trading, an increase of 101% from the average session volume of 472,034 shares. The stock had previously closed at $12.29.

Analyst Upgrades and Downgrades

A number of research firms have commented on OCS. HC Wainwright reduced their price target on shares of Oculis from $47.00 to $26.00 and set a “buy” rating on the stock in a research report on Monday. Stifel Nicolaus reduced their price target on shares of Oculis from $50.00 to $40.00 and set a “buy” rating on the stock in a research report on Monday. JPMorgan Chase & Co. reduced their price target on shares of Oculis from $42.00 to $23.00 and set an “overweight” rating on the stock in a research report on Wednesday. Wall Street Zen lowered shares of Oculis from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Oculis in a research report on Tuesday, April 21st. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $38.33.

Oculis Price Performance

The stock’s 50-day moving average price is $26.72 and its 200-day moving average price is $25.03. The company has a market capitalization of $685.90 million, a price-to-earnings ratio of -5.55 and a beta of 0.23. The company has a quick ratio of 5.18, a current ratio of 5.18 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS) last announced its earnings results on Friday, May 8th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.14). Oculis had a negative return on equity of 56.78% and a negative net margin of 8,460.67%.The company had revenue of $0.26 million for the quarter, compared to analyst estimates of $0.25 million. Equities research analysts anticipate that Oculis Holding AG will post -2.23 earnings per share for the current year.

Hedge Funds Weigh In On Oculis

A number of large investors have recently modified their holdings of OCS. Gildi lifeyrissjodur acquired a new position in Oculis in the fourth quarter valued at approximately $50,250,000. Aberdeen Group plc lifted its holdings in Oculis by 39.4% in the fourth quarter. Aberdeen Group plc now owns 1,746,946 shares of the company’s stock valued at $34,887,000 after buying an additional 493,827 shares during the period. SR One Capital Management LP raised its position in shares of Oculis by 98.8% during the 4th quarter. SR One Capital Management LP now owns 641,022 shares of the company’s stock valued at $12,801,000 after acquiring an additional 318,522 shares during the last quarter. Perceptive Advisors LLC bought a new stake in shares of Oculis during the 4th quarter valued at $9,862,000. Finally, Alyeska Investment Group L.P. raised its position in shares of Oculis by 152.3% during the 4th quarter. Alyeska Investment Group L.P. now owns 331,332 shares of the company’s stock valued at $6,617,000 after acquiring an additional 200,000 shares during the last quarter. 22.30% of the stock is currently owned by institutional investors and hedge funds.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.